Researchers Submit Patent Application, "Compositions And Methods For Preventing Rsv And Piv3 Infections", for Approval (USPTO 20240197865).

A patent application has been submitted by inventors from Saskatoon, Canada, for the development of subunit vaccine compositions to prevent and treat respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) infections. RSV and PIV3 are common causes of respiratory tract infections in infants and children, and currently, there are no licensed vaccines available for these infections. The invention involves the use of chimeric RSV-PIV3 antigens and immunogenic fusion proteins, along with adjuvants and mucoadhesive lipidic carriers, to enhance the efficacy of the vaccines. The patent application provides detailed information on the specific components used in the compositions. [Extracted from the article]